Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen's KRAS Inhibitor AMG 510 Leans Toward Tumor-Dependent, Not Agnostic, Approach

Executive Summary

SVP Elliott Levy said the company hasn't ruled out a tumor-agnostic approach for AMG 510, but Phase I data for the first-in-class drug show a bigger effect in lung cancer – a 50% response rate, so far – than in colorectal cancer patients with a KRAS G12C mutation.

You may also be interested in...



Merck Joins KRAS Stampede In Deal With Otsuka Affiliates

Merck & Co. is paying $50m up front to combine preclinical KRAS-target cancer compound pipelines with Astex and Taiho, both affiliates of Japan’s Otsuka. The two biotechs could realize up to $2.5bn in earnouts under the collaboration.

ESMO Preview: Five Key Oncology Battlegrounds To Watch

GSK looks to become a cancer contender once again, while Merck and Roche go toe-to-toe in TNBC.

Boehringer Ingelheim Snaps Up Lupin's MEK Inhibitor For Difficult-To-Treat Cancers

Boehringer Ingelheim intends to combine Lupin’s MEK inhibitor with its own KRAS inhibitors to target the oncogenic KRAS-RAF-MEK-ERK pathway, mutations in which drive many difficult-to-treat cancers.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1132972

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel